Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

Vincent Wai‐Sun Wong, Julien Vergniol, Grace Lai‐Hung Wong, Juliette Foucher, Henry Lik‐Yuen Chan, Brigitte Le Bail, Paul Cheung‐Lung Choi, Mathurin Kowo, Anthony Wing‐Hung Chan, Wassil Merrouche, Joseph Jao‐Yiu Sung, Victor de Lédinghen – 25 January 2010 – Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in affluent countries. Accurate noninvasive tests for liver injury are urgently needed.

Toxicant‐associated steatohepatitis in vinyl chloride workers

Matt Cave, Keith Cameron Falkner, Mukunda Ray, Swati Joshi‐Barve, Guy Brock, Rehan Khan, Marjorie Bon Homme, Craig J. McClain – 25 January 2010 – Although nonalcoholic steatohepatitis (NASH) is typically associated with obesity, it has also been reported to occur in lean individuals exposed to industrial chemicals. Occupational exposure to vinyl chloride (VC) is a well‐documented risk factor for hemangiosarcoma, but has not previously been associated with steatohepatitis. Here we evaluate liver biopsies from 25 nonobese, highly exposed VC workers for steatohepatitis.

Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors

Anna Ludovica Fracanzani, Alberto Piperno, Luca Valenti, Mirella Fraquelli, Sabina Coletti, Alessandra Maraschi, Dario Consonni, Enzo Coviello, Dario Conte, Silvia Fargion – 25 January 2010 – The clinical presentation of hereditary hemochromatosis has changed markedly in recent years. The aim of this study was to analyze a large series of consecutive Italian patients with hemochromatosis diagnosed between 1976 and 2007 to determine whether the genetic background and the presence of acquired risk factors influenced the severity of iron overload and the natural history of the disease.

Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis

Laura Pelletier, Sandra Rebouissou, Alain Paris, Estelle Rathahao‐Paris, Elisabeth Perdu, Paulette Bioulac‐Sage, Sandrine Imbeaud, Jessica Zucman‐Rossi – 25 January 2010 – Hepatocellular adenomas (HCAs) are benign liver tumors that usually develop in women who are taking oral contraceptives. Among these tumors, biallelic inactivating mutations of the hepatocyte nuclear factor 1α (HNF1A) transcription factor have been frequently identified and in rare cases of hepatocellular carcinomas developed in noncirrhotic liver.

Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: An analytical review

Lingyi Zhang, Guqi Wang, Weihong Hou, Ping Li, Andrea Dulin, Herbert L. Bonkovsky – 25 January 2010 – Chronic hepatitis B (CHB) is major global health problem. In China, where about 120,000,000 persons are chronically infected, CHB has been treated for centuries with traditional Chinese medicines (TCMs). This review summarizes and meta‐analyzes the results of randomized controlled trials (RCTs) of TCM formulations reported in China in 1998‐2008 for treatment of CHB.

Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

Vlad Ratziu, Fréderic Charlotte, Carole Bernhardt, Philippe Giral, Marine Halbron, Gilles LeNaour, Agnès Hartmann‐Heurtier, Eric Bruckert, Thierry Poynard, LIDO Study Group – 25 January 2010 – Short‐term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial histological results. Longer treatment might result in additional improvement. After a 1‐year randomized trial, 53 patients underwent a control liver biopsy and were enrolled in an open‐label extension trial of rosiglitazone (RSG), 8 mg/day for 2 additional years.

Subscribe to